DE69716469T2 - Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol - Google Patents

Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol

Info

Publication number
DE69716469T2
DE69716469T2 DE69716469T DE69716469T DE69716469T2 DE 69716469 T2 DE69716469 T2 DE 69716469T2 DE 69716469 T DE69716469 T DE 69716469T DE 69716469 T DE69716469 T DE 69716469T DE 69716469 T2 DE69716469 T2 DE 69716469T2
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
polyethylene glycol
osteogenese
composition containing
promoting agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69716469T
Other languages
English (en)
Other versions
DE69716469D1 (de
Inventor
Tetsuo Hoshino
Kazuhiro Saito
Susumu Iwasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69716469D1 publication Critical patent/DE69716469D1/de
Publication of DE69716469T2 publication Critical patent/DE69716469T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69716469T 1996-08-26 1997-08-25 Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol Expired - Lifetime DE69716469T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP22344396 1996-08-26
JP9040897 1997-04-09
PCT/JP1997/002941 WO1998008517A2 (en) 1996-08-26 1997-08-25 Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol

Publications (2)

Publication Number Publication Date
DE69716469D1 DE69716469D1 (de) 2002-11-21
DE69716469T2 true DE69716469T2 (de) 2003-02-20

Family

ID=26431895

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716469T Expired - Lifetime DE69716469T2 (de) 1996-08-26 1997-08-25 Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol

Country Status (9)

Country Link
US (1) US6190695B1 (de)
EP (1) EP0949927B1 (de)
AT (1) ATE226078T1 (de)
AU (1) AU3868997A (de)
CA (1) CA2264131A1 (de)
DE (1) DE69716469T2 (de)
ES (1) ES2181017T3 (de)
ID (1) ID18079A (de)
WO (1) WO1998008517A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
EP1087774A2 (de) * 1998-06-15 2001-04-04 Takeda Chemical Industries, Ltd. Zubereitungen, die bestimmte schewefelhaltende heterozyklische verbindungen enthalten, zur behandlung von knorpelerkrankungen
WO2000008018A1 (fr) 1998-08-07 2000-02-17 Takeda Chemical Industries, Ltd. Derives de benzothiepine, leur procede de preparation et leurs utilisations
AR020158A1 (es) * 1998-08-12 2002-04-10 Takeda Chemical Industries Ltd Mejorador del factor de induccion para la diferenciacion celular
AU6318900A (en) * 1999-08-05 2001-03-05 Takeda Chemical Industries Ltd. Pastes with the sustained release of osteogenesis promoter
CA2412888A1 (en) * 2000-06-23 2002-12-18 Takeda Chemical Industries, Ltd. Process for producing phospholipid-containing drug
KR100799143B1 (ko) * 2001-01-19 2008-01-29 히로노리 야마모또 내시경용 주사제
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US8158685B2 (en) * 2004-07-02 2012-04-17 Gregory Gene Steiner Method for bone growth
HUE056937T2 (hu) 2006-02-03 2022-04-28 Opko Renal Llc A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal
PT2679228T (pt) * 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
KR101959952B1 (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
PT2148684E (pt) * 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2008134518A2 (en) * 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
WO2009124210A1 (en) 2008-04-02 2009-10-08 Cytochroma Inc. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2015298858A1 (en) 2014-08-07 2017-03-02 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin D
CA3018019A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
DK656789A (da) 1988-12-28 1990-06-29 Takeda Chemical Industries Ltd Benzoheterocykliske forbindelser
DK0460488T3 (da) * 1990-05-30 2001-09-17 Takeda Chemical Industries Ltd Svovlholdige heterocykliske forbindelser
AU6586394A (en) * 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
JP3319625B2 (ja) * 1993-05-12 2002-09-03 ホーユー株式会社 速崩壊性生薬製剤
TW403757B (en) * 1994-12-28 2000-09-01 Takeda Chemical Industries Ltd Optically active benzothiepin derivative, its preparation and use
AU717260B2 (en) * 1995-06-05 2000-03-23 Takeda Chemical Industries Ltd. Osteogenetic promoting pharmaceutical composition

Also Published As

Publication number Publication date
ID18079A (id) 1998-02-26
WO1998008517A2 (en) 1998-03-05
WO1998008517A3 (en) 1998-05-07
EP0949927A2 (de) 1999-10-20
CA2264131A1 (en) 1998-03-05
US6190695B1 (en) 2001-02-20
ATE226078T1 (de) 2002-11-15
ES2181017T3 (es) 2003-02-16
DE69716469D1 (de) 2002-11-21
EP0949927B1 (de) 2002-10-16
AU3868997A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
DE69716469D1 (de) Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
DE69823869D1 (de) Pharmazeutische hydrogelformulierungen, vorrichtungen zur arzneistoffabgabe und verfahren
DE69808297T2 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
AR015946A1 (es) Formulacion farmaceutica que comprende bifosfonatos, proceso para su preparacion, uso de la formulacion para la fabricacion de un medicamento, metodo parala inhibicion de la reabsorcion osea, y metodo para el tratamiento y prevencion de osteoporosis
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE162073T1 (de) Pharmazeutische zusammensetzung zur behandlung von osteoporose enthaltend xanthohumol
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
IT1216686B (it) Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
ATE247981T1 (de) Proteinenthaltende pharmazeutische zubereitung
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
ATE247466T1 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne
WO1999050239A3 (fr) Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant
HRP20000781B1 (en) Effervescent preparations
DE69813263D1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
ATE402719T1 (de) Injiziebare pharmazeutische zusammensetzung enthaltend ethanol zur behandlung von bandscheibenvorfällen
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
ES2053679T3 (es) Embonato de azelastina, procedimiento para su preparacion y preparados farmaceuticos que contienen embonato de azelastina como principio activo.
HUP0002459A3 (en) Salts of optically active sulfoxide derivative, pharmaceutical compositions containing them and use thereof

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP

8364 No opposition during term of opposition